ReviewSeminars in oncology2012
The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.
Review in Seminars in oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 2 syntheses or guidelines pooled it, 145 citations in OpenAlex.
- Pooled it
- Is the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Pooled it
- Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study.BMC cancer · 2022Trial
- Cancer Vaccines: Mechanisms, Clinical Applications, Challenges, and Future Directions in Precision Medicine.Current cancer drug targets · 2026Review
- Article
- Article
- Efficacy and safety analysis of immune checkpoint inhibitor rechallenge in advanced esophageal squamous cell carcinoma: A retrospective study.Human vaccines & immunotherapeutics · 2025Article
- Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective.International journal of colorectal disease · 2024Review
- Combination Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer: A Review of Evidence.Cancer medicine · 2024Review
- Review
- Vaccines in Breast Cancer: Challenges and Breakthroughs.Diagnostics (Basel, Switzerland) · 2023Review
- Current Status and Challenges of Vaccination Therapy for Glioblastoma.Molecular cancer therapeutics · 2023Article
- Sustained release of tumor cell lysate and CpG from an injectable, cytotoxic hydrogel for melanoma immunotherapy.Nanoscale advances · 2023Article
- Local Liver Irradiation Concurrently Versus Sequentially with Cabozantinib on the Pharmacokinetics and Biodistribution in Rats.International journal of molecular sciences · 2023Article
- Chemotherapy: A partnership with immunotherapy in non-small cell lung cancer.Thoracic cancer · 2023Review
- Case report: Interstitial implantation radiotherapy combined with immunotherapy and GM-CSF in oligometastatic platinum-resistant ovarian cancer.Frontiers in immunology · 2023Article
- Combined radiotherapy and immune checkpoint inhibition for the treatment of advanced hepatocellular carcinoma.Frontiers in oncology · 2023Review
- Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies.Journal for immunotherapy of cancer · 2022Article
- Immune-awakeninActa pharmaceutica Sinica. B · 2022Article
- Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Therapeutic cancer vaccines are a unique treatment modality in that they initiate a dynamic process of activating the host immune system, which can then be exploited by concurrent or subsequent therapies. The addition of immunotherapy to standard-of-care cancer therapies has shown evidence of efficacy in preclinical models and in the clinical setting. This review examines the preclinical and clinical interactions between vaccine-mediated tumor-specific immune responses and local radiation, systemic chemotherapy, or select small molecule inhibitors, as well as the potential synergy between these modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.